XGene
Creating new, conjugated molecules that can be used to treat neurological disorders.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
N/A | Series B | ||
| Total Funding | 000k | ||
Related Content
Xgene Pharmaceutical, Inc. is a late clinical stage, venture capital-backed international company specializing in the development of novel, multimodal, conjugated molecules aimed at treating neurological disorders. Utilizing proprietary linker technology, Xgene focuses on enhancing the efficacy and tolerability of pain therapeutics. The company serves the pharmaceutical and biotechnology sectors, targeting clients who require advanced therapeutic solutions for neurological conditions. Operating in the global market, Xgene's business model revolves around research and development, clinical trials, and eventual commercialization of their proprietary treatments. Revenue is generated through venture capital funding, partnerships, and future sales of approved therapies.
Keywords: linker technology, multimodal molecules, neurological disorders, pain therapeutics, venture capital, clinical stage, pharmaceutical, biotechnology, research and development, global market.